Overview Study to Evaluate the Safety and PK of UI018 Status: Recruiting Trial end date: 2022-09-05 Target enrollment: Participant gender: Summary This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination formulation and co-administration. Phase: Phase 1 Details Lead Sponsor: Korea United Pharm. Inc.